Literature DB >> 31733082

Comparison of dermoscopic features between congenital and acquired acral melanocytic nevi in Korean patients.

D Roh1,2, K Shin1, W-I Kim1,2, M-Y Yang1, W-K Lee1,2, H-S Kim1, H-C Ko1,2, B-S Kim1,3, M-B Kim1,3.   

Abstract

BACKGROUND: The dermoscopic patterns of acral melanocytic nevi (AMNs) are crucial in differentiating them from acral melanoma. Several studies have reported the dermoscopic patterns of acquired acral melanocytic nevi (AAMNs). However, few have investigated the dermoscopic patterns of congenital acral melanocytic nevi (CAMNs).
OBJECTIVE: To compare the clinical and dermoscopic features of CAMNs and AAMNs.
METHODS: The present study included 43 patients with CAMNs and 40 with AAMNs. We reviewed their medical records as well as their clinical and dermoscopic findings.
RESULTS: Congenital acral melanocytic nevis were more asymmetrical than AAMNs (P = 0.002) and presented more frequently as comma-shaped (P = 0.005). Regarding dermoscopic findings, globular pattern (55.8%) was the most common feature of CAMNs, while parallel furrow pattern (37.5%) was the most common feature of AAMNs. The presence of fibrillar, globular, and parallel ridge patterns, and diffuse multi-component pigmentation differed significantly between the groups (P < 0.05). Furthermore, CAMNs showed melanoma-specific dermoscopic patterns, such as parallel ridge (18.6%) and diffuse multi-component pigmentation (25.6%).
CONCLUSION: The dermoscopic patterns of CAMNs and AAMNs differed markedly. In terms of dermoscopic patterns, CAMNs resembled acral melanoma more often than AAMNs did.
© 2019 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2020        PMID: 31733082     DOI: 10.1111/jdv.16089

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  1 in total

1.  Acral lentiginous melanoma in situ: dermoscopic features and management strategy.

Authors:  Byeol Han; Keunyoung Hur; Jungyoon Ohn; Sophie Soyeon Lim; Je-Ho Mun
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.